A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Summary

Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs. Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of standard treatment, but cabazitaxel has not yet been tested in patients with NSGCT.

Timeline

Start

2014-07-23

Primary completion

2022-04-29

Completion

2023-04-24

Drugs

Indications